CN112888696B - 外核苷酸酶抑制剂及其使用方法 - Google Patents

外核苷酸酶抑制剂及其使用方法 Download PDF

Info

Publication number
CN112888696B
CN112888696B CN201980054369.1A CN201980054369A CN112888696B CN 112888696 B CN112888696 B CN 112888696B CN 201980054369 A CN201980054369 A CN 201980054369A CN 112888696 B CN112888696 B CN 112888696B
Authority
CN
China
Prior art keywords
compound
alkyl
substituted
group
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980054369.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN112888696A (zh
Inventor
陈丽晶
R·J·比洛多
J·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antengene Corp Ltd
Original Assignee
Antengene Corp Ltd
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antengene Corp Ltd, Calithera Biosciences Inc filed Critical Antengene Corp Ltd
Publication of CN112888696A publication Critical patent/CN112888696A/zh
Application granted granted Critical
Publication of CN112888696B publication Critical patent/CN112888696B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201980054369.1A 2018-06-21 2019-06-20 外核苷酸酶抑制剂及其使用方法 Active CN112888696B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862688225P 2018-06-21 2018-06-21
US62/688225 2018-06-21
US201962827505P 2019-04-01 2019-04-01
US62/827505 2019-04-01
PCT/US2019/038245 WO2019246403A1 (en) 2018-06-21 2019-06-20 Ectonucleotidase inhibitors and methods of use thereof

Publications (2)

Publication Number Publication Date
CN112888696A CN112888696A (zh) 2021-06-01
CN112888696B true CN112888696B (zh) 2024-04-16

Family

ID=68981317

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980054369.1A Active CN112888696B (zh) 2018-06-21 2019-06-20 外核苷酸酶抑制剂及其使用方法

Country Status (16)

Country Link
US (3) US11078228B2 (enExample)
EP (1) EP3810617A4 (enExample)
JP (1) JP7538047B2 (enExample)
KR (1) KR102902754B1 (enExample)
CN (1) CN112888696B (enExample)
AU (1) AU2019288495B2 (enExample)
BR (1) BR112020025132B1 (enExample)
CA (1) CA3104088A1 (enExample)
CL (1) CL2020003339A1 (enExample)
CO (1) CO2021000049A2 (enExample)
IL (1) IL279475B2 (enExample)
MX (1) MX2020013320A (enExample)
PH (1) PH12020552214A1 (enExample)
SG (1) SG11202012001YA (enExample)
TW (1) TWI911140B (enExample)
WO (1) WO2019246403A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102638592B1 (ko) 2016-12-22 2024-02-19 안텐진 테라퓨틱스 리미티드 엑토뉴클레오티다제 억제제 및 이의 용도
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
CA3098493A1 (en) 2018-04-30 2019-11-07 Oric Pharmaceuticals, Inc. Cd73 inhibitors
KR102902754B1 (ko) * 2018-06-21 2025-12-19 안텐진 테라퓨틱스 리미티드 엑토뉴클레오티다제 저해제 및 이의 사용 방법
TWI821559B (zh) * 2019-04-28 2023-11-11 大陸商上海和譽生物醫藥科技有限公司 一種cd73抑制劑，其製備方法和應用
CA3143496A1 (en) * 2019-06-20 2020-12-24 Antengene Therapeutics Limited Ectonucleotidase inhibitors and methods of use thereof
US12544391B2 (en) 2019-07-16 2026-02-10 Oric Pharmaceuticals, Inc. CD73 inhibitors
CN116854758A (zh) 2019-10-30 2023-10-10 欧瑞克制药公司 Cd73抑制剂
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
CN116375772B (zh) * 2023-02-13 2024-11-01 北京先通国际医药科技股份有限公司 腺苷的制备方法及其用途
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201811775A (zh) * 2016-09-09 2018-04-01 美商卡利泰拉生物科技公司 外核苷酸酶抑制劑及其使用方法
WO2018208980A1 (en) * 2017-05-10 2018-11-15 Oric Pharmaceuticals, Inc. Cd73 inhibitors
WO2018208727A1 (en) * 2017-05-08 2018-11-15 Eternity Bioscience Inc. Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
CN110402249A (zh) * 2016-12-22 2019-11-01 卡利泰拉生物科技公司 外核苷酸酶抑制剂及其使用方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019638A1 (en) 1991-04-24 1992-11-12 Yamasa Shoyu Kabushiki Kaisha 1-β-D-ARABINOFURANOSYL-(E)-5-(2-HALOGENOVINYL)-URACIL DERIVATIVE
WO1994010128A1 (en) 1992-11-02 1994-05-11 Affymax Technologies N.V. Novel photoreactive protecting groups
US5635608A (en) 1994-11-08 1997-06-03 Molecular Probes, Inc. α-carboxy caged compounds
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
NL1005244C2 (nl) 1997-02-10 1998-08-18 Inst Voor Agrotech Onderzoek Oppervlakte-actieve aminen en glycosiden.
WO2004096233A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Nucleoside phosphonate conjugates
EP1860113A1 (en) 2006-05-24 2007-11-28 Rheinische Friedrich-Wilhelms-Universität Bonn Ectonucleotidase inhibitors
EP2040712B1 (en) * 2006-07-18 2011-03-02 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
WO2009061781A1 (en) 2007-11-07 2009-05-14 Schering Corporation Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
EP2070938A1 (en) * 2007-12-13 2009-06-17 Heidelberg Pharma AG Clofarabine dietherphospholipid derivatives
CA2684017A1 (en) 2009-10-22 2011-04-22 Universite Laval Ectonucleotidase pyrophosphate/phosphodiesterase-1 (enpp-1) as a target for the treatment of aortic valve stenosis and cardiovascular calcification
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
CN103209970B (zh) 2010-07-08 2016-08-24 生命科技公司 原位化学发光底物和测定
CN102311472B (zh) 2010-07-09 2014-09-03 神隆(昆山)生化科技有限公司 2-氯-9-(2’-脱氧-2’-氟-β-D-阿拉伯呋喃糖基)-腺嘌呤的制备
KR101960113B1 (ko) 2011-05-03 2019-03-19 라이프 테크놀로지스 코포레이션 섬광 및 백열광 １,２-디옥세탄들
EP3517539B1 (en) * 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
GB201220843D0 (en) 2012-11-20 2013-01-02 Univ College Cork Nat Univ Ie Compound
CN106463125B (zh) * 2014-04-25 2020-09-15 杜比实验室特许公司 基于空间元数据的音频分割
EP3134411B1 (en) 2014-04-25 2021-06-30 Boehringer Ingelheim International GmbH Purine derivatives as cd73 inhibitors for the treatment of cancer
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
DK3362461T3 (da) 2015-10-16 2022-05-09 Modernatx Inc Mrna-cap-analoger med modificeret phosphatbinding
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
US10611790B2 (en) 2015-11-02 2020-04-07 Mitobridge, Inc. Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases
JP6411676B2 (ja) * 2015-12-03 2018-10-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｓｔｉｎｇの調節因子としての環状プリンジヌクレオチド
US10794113B2 (en) * 2016-12-22 2020-10-06 Marketing Displays, Inc. Compact privacy screen
CN109503587B (zh) * 2017-09-14 2022-01-11 辽宁利锋科技开发有限公司 双杂环三氮唑核苷类似物的抗肿瘤作用与应用
US11377469B2 (en) * 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
CA3098493A1 (en) * 2018-04-30 2019-11-07 Oric Pharmaceuticals, Inc. Cd73 inhibitors
TW202017569A (zh) * 2018-05-31 2020-05-16 美商佩樂敦治療公司 用於抑制cd73之組合物及方法
KR102902754B1 (ko) 2018-06-21 2025-12-19 안텐진 테라퓨틱스 리미티드 엑토뉴클레오티다제 저해제 및 이의 사용 방법
CA3143496A1 (en) 2019-06-20 2020-12-24 Antengene Therapeutics Limited Ectonucleotidase inhibitors and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201811775A (zh) * 2016-09-09 2018-04-01 美商卡利泰拉生物科技公司 外核苷酸酶抑制劑及其使用方法
CN110402249A (zh) * 2016-12-22 2019-11-01 卡利泰拉生物科技公司 外核苷酸酶抑制剂及其使用方法
WO2018208727A1 (en) * 2017-05-08 2018-11-15 Eternity Bioscience Inc. Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
WO2018208980A1 (en) * 2017-05-10 2018-11-15 Oric Pharmaceuticals, Inc. Cd73 inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Design and Synthesis of r-Carboxy Phosphononucleosides;Sebastien Debarge 等;《J. Org. Chem.》;第76卷;第105-126页 *
α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5′-Nucleotidase (CD73) Inhibitors;Sanjay Bhattarai 等;《J. Med. Chem.》;第58卷;第6248-6263页 *

Also Published As

Publication number Publication date
MX2020013320A (es) 2021-02-22
WO2019246403A1 (en) 2019-12-26
IL279475A (en) 2021-01-31
PH12020552214A1 (en) 2021-08-16
US20230022922A1 (en) 2023-01-26
BR112020025132A2 (pt) 2021-03-23
AU2019288495A1 (en) 2021-01-28
EP3810617A1 (en) 2021-04-28
KR102902754B1 (ko) 2025-12-19
EP3810617A4 (en) 2022-06-29
US11858957B2 (en) 2024-01-02
CO2021000049A2 (es) 2021-04-19
AU2019288495B2 (en) 2024-02-08
NZ771648A (en) 2025-08-29
US20240132533A1 (en) 2024-04-25
JP7538047B2 (ja) 2024-08-21
TWI911140B (zh) 2026-01-11
IL279475B1 (en) 2025-09-01
US12421273B2 (en) 2025-09-23
IL279475B2 (en) 2026-01-01
US11078228B2 (en) 2021-08-03
TW202010750A (zh) 2020-03-16
US20190389899A1 (en) 2019-12-26
CL2020003339A1 (es) 2021-06-25
KR20210024561A (ko) 2021-03-05
CA3104088A1 (en) 2019-12-26
BR112020025132B1 (pt) 2023-10-10
CN112888696A (zh) 2021-06-01
JP2021529172A (ja) 2021-10-28
SG11202012001YA (en) 2021-01-28

Similar Documents

Publication Publication Date Title
US12421273B2 (en) Ectonucleotidase inhibitors and methods of use thereof
US11034715B2 (en) Ectonucleotidase inhibitors and methods of use thereof
TWI767937B (zh) 外核苷酸酶抑制劑及其使用方法
JP2023022165A (ja) インターフェロン遺伝子刺激因子依存性シグナル伝達のアゴニストとしての環状ジヌクレオチド
KR102782200B1 (ko) 인터페론 유전자 조절인자의 자극제로서의 환식 다이-뉴클레오타이드
WO2019125974A1 (en) Cyclic di-nucleotide compounds as sting agonists
HK40049700A (en) Ectonucleotidase inhibitors and methods of use thereof
HK40049700B (en) Ectonucleotidase inhibitors and methods of use thereof
EA046381B1 (ru) Ингибиторы эктонуклеотидазы и способы их применения
NZ790347A (en) Ectonucleotidase inhibitors and methods of use thereof
HK40017040A (en) Ectonucleotidase inhibitors and methods of use thereof
HK40022356A (en) Cyclic di-nucleotides as stimulator of interferon genes modulators
HK40013556A (en) Ectonucleotidase inhibitors and methods of use thereof
HK40013556B (en) Ectonucleotidase inhibitors and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40049700

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230330

Address after: Kowloon, Hongkong, China

Applicant after: Deqi Medical Co.,Ltd.

Address before: California, USA

Applicant before: CALITHERA BIOSCIENCES, Inc.

GR01 Patent grant
GR01 Patent grant